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Danish National Patient RegistryBackground: There are limited estimates of the incidence rates (IRs) of mastocytosis, and only a few stud-
ies have addressed the long-term consequences of living with these diagnoses. Previous reports have
shown that systemic mastocytosis is associated with leukemic transformations and an increased risk
of death as opposed to cutaneous mastocytosis (CM) and indolent systemic mastocytosis (ISM), which
have benign diagnoses with life expectancy rates similar to those of the background population.
Objective: This study aimed to analyze the incidence and mortality of mastocytosis.
Methods: A population-based matched cohort study of patients with mastocytosis between 1 January 1,
1977 and 31 December 31, 2014 was identified from the Danish National Health Registries. IRs of CM,
ISM, and pediatric mastocytosis were highlighted. Survival estimates were compared with those of a
healthy background population, using a Cox proportional hazard model.
Results: A total of 1461 patients with mastocytosis were identified. The annual IR of overall mastocytosis
was 1.1 per 100,000 person years (95% confidence interval [CI], 1.0–1.2). Among children, the IR was 1.8
per 100,000 person years (95% CI, 1.6–2.1). The prevalence of any comorbidity was twice as high among
patients with mastocytosis compared with the population without mastocytosis (odds ratio: 2.1; 95% CI,
1.8–2.5). The Charlson Comorbidity Index–adjusted mortality among adult patients with mastocytosis
was HRCutaneous Mastocytosis 1.2 (95% CI, 0.8–1.9), HRIndolent Systemic Mastocytosis 1.9 (95% CI 1.4–2.5), and
HRSystemic Mastocytosis 4.2 (95%, CI 1.9–9.4), respectively.
Conclusion: Based on an entire nation, with free health care at the point of access, we estimated an annual
IR of mastocytosis and its subgroups. We discovered that patients with ISM had an increased risk of death
compared with the general population. Our data supported the overall benign nature of CM diagnosed
after age 2 years.
 2020 The Authors. Published by Elsevier Inc. on behalf of Women’s Dermatologic Society. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Mastocytosis is a heterogeneous group of rare mast cell disor-
ders that may affect both children and adults. Mastocytosis is
divided into three major disease categories: cutaneous mastocyto-
sis (CM), systemic mastocytosis (SM), and localized mast cell
tumors (Valent et al., 2017). The first case of CM was reported in
1869 and the first case of SM in 1949, but there was no interna-
tional consensus on how to differentiate CM from SM or vice versa
until 2001 (Valent et al., 2001).Pediatric cases of mastocytosis are almost always benign and in
the category of CM, where spontaneous remission is a well-known
phenomenon. However, a few cases of pediatric SM have been
reported with onset before the age of 2 years and mostly as cases
of diffuse CM, which is associated with anaphylaxis, gastrointesti-
nal bleeding, and bullous erythrodermia (Ben-Amitai et al., 2005;
Burnett et al., 2007; Ghiasi et al., 2011; Lange et al., 2013; Meni
et al., 2015). Aggressive subtypes of mastocytosis are thus reported
in infants and in patients aged 60 years (Bodemer et al., 2010;
Escribano et al., 2009). More than 30% of those with adult-onset
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et al., 2007). Age at onset and clinical subtype are thus prognostic
factors in the clinical assessment of patients with mastocytosis.
SM is associated with leukemic transformation and an
increased risk of death (Pardanani, 2015), but patients with indo-
lent SM (ISM) reportedly have life expectancy rates that are similar
to those of the background population (Escribano et al., 2009). In
2016, a subcategory of ISM was finally accepted: smoldering SM
(SSM). These patients were observed to have a less favorable prog-
nosis than those with ISM, but a superior prognosis when com-
pared with patients with aggressive SM and mast cell leukemia
(Table 1; Arber et al., 2016). Epidemiologic studies on long-term
outcomes in larger mastocytosis cohorts are limited and biased
toward aggressive subtypes of SM (tertiary center cases).
The scope of this study was to examine the incidence of masto-
cystosis in Denmark between January 1977 and December 2014.
We investigated the long-term survival of people with CM, SM,
and ISM adjusted for sex and age as well as competing comorbidi-
ties using the Charlson Comorbidity Index (CCI) score.
Methods
Design
In this population-based cohort study, patients with mastocyto-
sis between January 1, 1977 and December 31, 2014 were identi-
fied in the Danish National Health Registries. The study was
approved by the Danish Health Authority (project no. 3-3013-
338/1) and reported in accordance with the Reporting of Studies
Conducted using Observational Routinely Collected Data State-
ment (Benchimo et al., 2016; Vandenbroucke et al., 2007).
Data sources
Civil registration system
All live-born citizens in Denmark are assigned a personal social
security number, the Civil Personal Register number. This number
is included in all Danish health and public registries and was used
to facilitate the extraction of individual diagnoses and vital status
of the participants in the present study (Schmidt et al., 2014).
Information is updated on a daily basis.
Danish National Patient Registry
The Danish National Patient Registry contains information on
all hospital admissions from January 1, 1977. For each admission,
a record of diagnoses is registered, with the primary (or A-) diagno-
sis being the cause of admission. Existing or adjacent diseases are
registered as secondary (or B-) diagnoses (Schmidt et al., 2015).
From January 1, 1995, diagnoses from all outpatient and emer-
gency room visits were added. The International Classification of
Diseases (ICD), version 8, codes were used until 1994 and versionTable 1
The World Health Organization classification of mastocytosis in 2016 (Valent et al.,
2017).
Cutaneous mastocytosis (CM)
Maculopapular CM (urticaria pigmentosa)
Diffuse CM




SM with clonal hematologic non-mast cell-lineage disease
Aggressive SM
Mast cell leukemia
Mast cell sarcoma10 (ICD10) codes thereafter. Diagnostic coding is a mandatory pro-
cedure in all discharge summaries and is conducted by physicians
exclusively.
Danish Pathology Registry
The Danish Pathology Registry was established in 1997 as a
coorporation between the Danish Society of Pathologists and the
National Board of Health Data. This registry contains diagnoses
(SNOMED diagnoses) as assessed by trained pathologists on all cell
and tissue samples in primary, secondary, and tertiary health care
settings. The registry contains data on almost 100% of pathologic
samples (Bjerregaard and Larsen, 2011).
Study population
Diagnostic codes for mastocytosis were used to screen and
identify people with mastoctytosis from either of two registries:
Danish National Patient Registry or Danish Pathology Registry
(Supplementary A). Baseline for each individual refers to the first
date in an individual’s record on which the diagnosis of mastocyto-
sis was noted. Ten age- and sex-matched individuals, per patient
with mastocytosis, entered the study on the same date. A cohort
of 1461 patients with mastocytosis and 14,610 people without
mastocytosis were compared in terms of demographic characteris-
tics and comorbidities at baseline. Patients with mastocytosis were
identified from January 1, 1994 to December 31, 2014 and catego-
rized as CM, ISM, or SM. Age was categorized as infant (0–1 years of
age), child (2–15 years of age), young adult (16–60 years of age),
and older adult (age  60 years) for descriptive and analytical pur-
poses. The ICD version 8 codes did not allow for us to distinguish
between subgroups of mastocytosis; thus, the epidemiologic anal-
yses were restricted to the ICD10 period.
Comorbidity
The CCI was introduced in 1987 as a new method to assess the
risk of death from comorbid disease categories in longitudinal
studies. The index consists of 19 chronic diseases that are weighted
in proportion to severity (Charlson et al., 1987). The CCI is widely
used to assess comorbidity among adults with a wide spectrum
of diseases (Quan et al., 2011). In this study, baseline comorbidity
was based on prior and present diagnoses included in the CCI (Sup-
plementary B). Diagnoses were recorded as a binary (0 or CCI
weight) as well as categorized variable (low [0], moderate [1–2],
or high [3]). The CCI has not been validated for use in pediatric
populations, but children were not included in the comorbidity
and CCI-adjusted mortality analyses.
Statistical analysis
Incidence rates (IRs) of childhood (<16 years of age) mastocyto-
sis were assessed during the complete study period, and we calcu-
lated the Danish childhood prevalence as of December 31, 2014
(Statistics Denmark, 2016).
Statistical analyses were defined beforehand and performed
using STATA, version 13.1 (Stata Statistical Software). Prospective
analyses were conducted, following the cohort from staggered
entry until the time of death, loss to follow-up, or end of follow-
up (December 31, 2014), whichever came first. Influent covariates
were assessed on the basis of the literature and a preanalytic direc-
ted acyclic graph (Supplementary C). Age was strongly associated
with the CCI, and adjustment of either sex and age or sex and
CCI appeared to deliver the most reliant results. We used a logistic
regression model to compare baseline CCI scores (0 or >0).
We identified all deaths in patients with mastocytosis and
matched individuals. The Kaplan-Meier model was used to com-
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A Cox regression model adjusting for age (categorical) and sex was
used to compare the risk of death. Stratified analyses were under-
taken to determine whether there was effect modification by age.
Assumptions on proportional hazards were fulfilled as evaluated
from graphic assessments of log–log plots.Results
A total of 1300 patients with mastocytosis were identified dur-
ing the ICD10 period. Of these, 25 patients were excluded, either
because the inclusion date came after the registered date of death
(n = 1) or because the ICD10 diagnoses were registered before the
official date of the ICD10 implementation (n = 24). Thus, IRs and
mortality analyses were based on 1275 cases of mastocytosis.
The study population was followed for a median of 9 years (in-
terquartile range [IQR], 4–17 years) and pediatric cases for a med-
ian of 8 years (IQR, 4–14 years).
Of the 1436 patients with mastocytosis (Table 2), 1005 (70%)
were adults with a median age at onset of 48 years (IQR, 36–
61 years). The male-to-female ratio was 2:3 in adult cases. More
men than women were classified as SM cases (73%), excluding
cases of ISM. A total of 431 patients (30%) were diagnosed during
childhood, and 273 of these patients (63%) were diagnosed within
the first 2 years of life. The median age at onset was 10 months
among infants (IQR, 6–13 months) and 4.5 years in the child popu-
lation (IQR, 2.8–8.0 years). The male-to-female ratio among chil-
dren was 3:2, and the majority of pediatric cases had diagnoses
of CM (95%).
Incidence
The annual IR of mastocytosis was 1.1 cases per 100,000 person
years (95% confidence interval [CI], 1.0–1.2). There was no trend in
the frequency of diagnoses over time (data not shown). The annual
IR of CM was 0.75 cases per 100,000 person years (95% CI, 0.7–0.9),
whereas the IR of ISM was 0.4 cases per 100,000 person years (95%
CI, 0.3–0.5). The annual IR among children (age < 16 years) was 1.8
cases per 100,000 person years (95% CI, 1.6–2.1), and the preva-
lence of pediatric mastocytosis as of December 31, 2014 was 2.5
cases per 10,000 children.
Comorbidities
Adult ISM and SM cases had a higher baseline prevalence of
chronic comorbidities (Table 3). In the multivariate analysis model,
CCI-adjusted hazard ratios (HRs) did not differ significantly from
the HRs from the age-adjusted analyses. Comorbidities with a
higher prevalence were metastatic cancers with unknown localiza-
tion (ORMAST 9.3; 95% CI, 5.1–17.1), chronic pulmonary diseases
(ORMAST 1.7; 95% CI, 1.1–2.5), and connective tissue diseases
(ORMAST 2.3; 95% CI, 1.3–4.0).
Survival
During 125,115 person years of follow-up, a total of 1405 per-
sons (10%) died, 186 (15%) from the patient group and 1219
(10%) from the comparison group. Four of seven childhood deaths
occurred in patients with mastocytosis (findings not presented to
preserve confidentiality). A total of 248 persons (1.8%) were cen-
sored due to emigration or loss to follow-up. The relative 5-year
survival was 1.0 (95% CI, 1.0–1.0) in the adult CM group, 0.8 (95%
CI, 0.8–0.9) in the ISM group, and 0.4 (95% CI, 0.3–0.7) in the SM
group. The raw survival data on CM cases diagnosed between
1977 and 2014 were similar to those of the background populationand showed a tendency toward a protective effect (data not
shown).
Overall, patients with mastocytosis had a higher mortality rate
compared with the background population (Table 4). When strati-
fied by CM, ISM, and SM, the age- and sex-adjusted HRs were all
significantly higher than within the comparison group. The
decreased survival over time is illustrated in Fig. 1. Age was an
effect modifier; thus, estimates were reported in relevant age
strata. When adjusting for baseline CCI, the survival of patients
with CM and ISM moved toward one (Table 4; columns 2–3).Discussion
To our knowledge, this is the largest cohort of patients with
mastocytosis ever presented. Follow-up was obtained over a per-
iod of almost 40 years, and the data were derived from one of
the oldest and most complete population registries in the world.
Epidemiology
Our findings corroborate those of a Danish study that estimated
an annual IR of SM, including ISM, of 0.89 per 100,000 person years
(Broesby-Olsen et al., 2016). A Dutch cross-sectional study found a
prevalence of adult ISM of at least 13 cases per 100,000 person
years (van Doormaal et al., 2013). The corresponding point preva-
lence in our case was 18 per 100,000 person years.
We discovered that 62% of all pediatric patients with mastocy-
tosis were diagnosed before 2 years of age. This percentage was
considerably lower than the 90% reported by Meni et al. (2015),
but because our results are based on unselected register-based
information, we believe that the percentage of infantile onset is
closer to 60% than to 90% of all pediatric cases, which is in line with
the findings of Schena et al. (2016).
Survival
Patients with ISM and SM had a significantly increased risk of
death, which was detectable after 1 year of follow-up. Considering
the number of CM diagnoses in the adult population (n = 497),
there is a chance of historical misclassification of ISM cases into
an adult CM category, as pointed out in the study by Broesby
et al. (2016), where adult cases of urticaria pigmentosa were
consequently categorized as probable ISM. We observed an
increased hazard of death in those with ISM and SM in all analyses.
Several studies emphasize the inferior survival of adult patients
with SM, but only two studies address the decreased survival in the
ISM patient category (Cohen et al., 2014; Pardanani, 2010). In the
first study, the inferior survival among patients with ISM was
downsized as a result of the misclassification of SM cases into
the ISM category. The latter study acknowledged a lower survival
in patients with SSM, a rare and slowly progressing subvariant of
ISM that was mentioned for the first time by Valent et al. (2001).
There is reason to believe that historical ISM cases may have
progressed into SSM during the follow-up period, which may
explain the observed decreased survival of patients with ISM in
our study.
SSM was not included as an independent disease category until
the 2016 World Health Organization Disease Classification; thus, it
was impossible for us to redefine ISM cases into a new disease cat-
egory not defined at the time of the data collection process. There-
fore, survival estimates of patients with ISM in the present study
should be interpreted with caution, although some adult patients
with CM may have been misclassified as ISM cases or people
who had SSM may have been included in the ISM category to
reduce the survival of this group. Subgroup-specific HRs were
Table 2






















Age categories, n (%), y
0–1 273 (19) 231 (27) 12 (3) 0 (0) 30 (19)
2–14 158 (11) 128 (15) 4 (1) 1 (4) 25 (16)
15 1005 (70) 497 (58) 377 (96) 25 (96) 106 (66)
Mean age (±SD), y 35 (±26) 28 (±24) 52 (±21) 61 (±16) 29 (±24)
Median age, y (25/75 percentiles)
0–1 0.8 (0.5/1.1) 0.7 (0.5/1.1) 0.7 (0.5/0.8) NA 1.0 (0.6/1.4)
2–14 4.5 (2.8/8.0) 4.6 (2.8/8.4) 5.3 (3.1/7.6) 6.5 (NA) 4.4 (3.2/6.5)
15 47.5 (36.4/61.4) 45.1 (33.7/56.4) 51.3 (40.2/69.5) 65.0 (55.4/72.5) 45.4 (35.4/54.8)
Year of diagnosis
1977–1993 161 (11) 9 (1) 12 (3) 0 (0) 161 (100)
1994–2000 398 (28) 205 (24) 181 (46) 9 (35) NA
2001–2014 877 (61) 642 (75) 200 (51) 17 (65) NA
Follow-up, y (25/75)*
Median age at 49 (22/68) 37 (14/58) 64 (50/79) 71 (58/84) 59 (34/77)
Median years of 8.6 (3.3/16.0) 7.5 (3.7/13.2) 6.9 (1.1/15.5) 0.8 (0.2/5.3) 27.6 (22/33)
Sex
Female 761 (53) 462 (54) 208 (53) 7 (27) 84 (52)
Male 675 (47) 394 (46) 185 (47) 19 (73) 77 (48)
CCI scores at baseline
Low (0) 1217 (83) 776 (90) 273 (67) 8 (31) 160 (99)
Moderate (1–2) 198 (14) 79 (9) 103 (25) 15 (58) 198 (14)
High (3) 46 (3) 12 (1) 31 (8) 3 (11) 46 (3)
Mean CCI (95% CI)y 0.36 (0.31–0.41) 0.17 (0.13–0.20) 0.81 (0.67–0.96) 1.69 (1.03–2.36) 0.01 (-0.01–0.02)
Bone marrow biopsy
Performed in cases 275 (19) 148 (17) 105 (26) 13 (50) 9 (6)
Children 6 (1.4) 5 (1.4) 0 (0) 0 (0) 1 (1.5)
Adults 269 (26) 143 (28) 105 (27) 13 (52) 8 (8)
Diagnostic units
Dermatology 574 (40) 413 (48) 102 (26) 2 (8) 57 (41)
Allergology 101 (7) 78 (9) 21 (5) 1 (4) 1 (1)
Paediatrics 114 (8) 77 (9) 0 (0) 0 (0) 37 (26)
Hematology 99 (7) 41 (5) 42 (11) 4 (15) 12 (4)
Emergency units 14 (1) 8 (1) 6 (1) 0 (0) 0 (0)
Internal medicine 144 (10) 48 (6) 42 (11) 9 (35) 15 (23)
Surgery 185 (13) 59 (7) 114 (29) 3 (12) 9 (4)
Pathology 193 (13) 125 (15) 61 (15) 7 (27) 0 (0)
Other 12 (1) 7 (1) 5 (1) 0 (0) 0 (0)
CI, confidence interval; CCI, Charlson Comorbidity Index; ICD, International Classification of Diseases; SD, standard deviation.
Patients identified by the ICD10 diagnostic code system (1994–2014) were divided into cutaneous, indolent systemic, and systemic mastocytosis cohorts. Patients identified
from 1977–1993 relied on the ICD8 diagnostic code system. Figures are numbers with appertaining percentages. Continuous variables are presented with appertaining SDs or
25/75 percentiles.
* For the purpose of survival analysis, patients were followed from time of diagnosis until death, end of follow-up (December 31, 2014), or loss to follow-up.
y The prevalence of chronic comorbidities was compared to a sex- and age-matched nonmastocytosis group with mean CCI = 0.14 (0.13–0.15).
 Mastocytosis diagnosis based exclusively upon diagnosis from the Danish National Pathology Register.
Table 3
ORs and 95% CIs on comorbidities at baseline in adult (15 years of age) patients with mastocytosis compared with age- and sex-matched unexposed population (n = 8920).
Mastocytosis No. Crude risk of CCI  1
OR (95% CI)
Adjusted risk of CCI  1
OR (95% CI)*
Adjusted risk of CCI  1
OR (95% CI)y
Mastocytosis overall 891 2.10 (1.80–2.45) 2.44 (2.06–2.90) 1.63 (1.35–1.97)
Cutaneous mastocytosis 489 1.26 (0.98–1.62) 1.50 (1.15–1.94) 1.57 (1.19–2.08)
Indolent systemic mastocytosis 377 3.51 (2.82–4.39) 3.47 (2.75–4.39) 1.83 (1.38–2.41)
Systemic mastocytosis 25 17.37 (7.24–41.69) 12.31 (4.89–30.99) 1.63 (0.63–4.19)
CI, confidence interval; OR, odds ratio.
Charlson Comorbidity Index scores (CCI) were dichotomised into 0 or 1.
* Adjusted for age (> or <60 years of age) and gender.
y Sensitivity analysis omitting diagnoses of lymphoma, leukaemia and non-metastatic solid tumour categories (C00-C75, C91-C95, C81-C85, C88, C90, C96).
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were reclassified as ISM or SM during follow-up.
In a literary review, 2.9% of pediatric patients with mastocytosis
were reported to have a fatal outcome (Meni et al., 2015). In this
study, children with SM were overrepresented, and no control
group was included for comparison. In the present study, patients
with childhood mastocytosis had a significantly different survivalprofile compared with children in the background population.
However, the comparison was based on three versus four deaths
among children of 0–1 year of age (HR: 15.23; range, 2.54–
91.12), and there is a substantial risk that this estimate could have
been related to chance, supported by the width of the CIs. Another
explanation could be that these children may have had the rare dif-
fuse CM; this diagnosis was not observed in this dataset.
Table 4
Crude and adjusted HR of death among patients registered with diagnosis of mastocytosis during the period from January 1, 1994 to December 31, 2014 (n = 1275).
Mastocytosis Outcome (n)* Crude risk of death
HR (95% CI)
Adjusted risk of death
HR (95% CI)y
Adjusted risk of death
HR (95% CI)
Mastocytosis all 186 1.64 (1.40–1.91) 2.13 (1.83–2.49) 1.71 (1.46–2.01)
CM 55 0.71 (0.54–0.93) 1.34 (1.02–1.76) 0.80 (0.61–1.06)
0– 1 year 0.14 (0.04–0.42) 15.23 (2.54–91.12) NA
2–15 years 0.07 (0.01–0.52) 10.49 (0.66–167.65) NA
16–60 years 0.53 (0.34–0.83) 1.33 (0.84–2.12) 1.26 (0.79–2.01)
60 years 6.02 (4.24–8.57) 1.24 (0.87–1.77) 1.15 (0.81–1.64)
ISM 114 3.24 (2.67–3.93) 2.59 (2.14–3.14) 1.53 (1.25–1.86)
0–1 year NA NA NA
2–15 years NA NA NA
16–60 years 0.95 (0.65–1.39) 2.21 (1.48–3.28) 1.97 (1.33–2.92)
60 years 13.86 (11.15–17.24) 2.73 (2.19–3.41) 1.80 (1.42–2.27)
SM 17 18.42 (11.41–29.75) 6.60 (4.08–10.68) 5.58 (3.44–9.07)
0–1 year NA NA NA
2–15 years NA NA NA
16–60 years 13.18 (4.93–35.21) 37.07 (13.79–99.62) 26.01 (9.66–70.01)
60 years 31.80 (18.39–54.97) 5.48 (3.17–9.51) 3.08 (1.76–5.36)
CI, confidence interval; CM, cutaneous mastocytosis; HR, hazard ratio; ISM, indolent systemic mastocytosis; SM systemic mastocytosis.
Estimates are presented in clinically relevant age strata. HRs refer to the unexposed population (n = 12,760).
* The number of outcomes (deaths) within age strata were omitted in agreement with the national laws on protection of data referable to an individual level.
y Adjusted for age (categorical) and sex.
 Adjusted for Charlson Comorbidity Index score (categorical) and sex.
Fig. 1. Confounding variables and their influence during a period of twenty years of follow up.
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This study was designed to overcome some of the methodolog-
ical limitations of previous epidemiologic mastocytosis studies.
The study was based on almost all Danish patients with mastocy-
tosis over an extensive period of time. The cohort was identified
from Danish National Health Registries, which offer unique possi-
bilities for epidemiologic research on unselected groups with a
high validity overall (Bjerregaard and Larsen, 2011; Schmidt
et al., 2014, 2015; Zuberbier et al., 2009). To include the full spec-
trum of mastocytosis and minimize the risk of selection bias, two
international diagnostic code systems (ICD and SNOMED) and reg-
istries were used for patient identification.
We used a matched cohort design to ensure adequate groups for
comparison and adjusted analyses when assessing the prevalenceof comorbidities or death as a prospective outcome within each
subgroup of mastocytosis. The CCI has not been validated for use
in mastocytosis but is recognized as a valid prognostic tool in less
rare disease categories. Contrary to the study by Broesby et al.
(2016), the effect of a weighted baseline CCI was tested as an influ-
ent variable in our prospective survival analyses. Our data suggest
that adults with CM have a normal life expectancy rate, especially
if data are adjusted for the effect of existing baseline chronic
comorbidities.
Limitations
Although the use of register-based data minimizes the risk of
selection bias, the risk of a misclassification of the acquired data
is present. The distribution of ISM/SM was consistent with the lit-
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[2014]). We were limited by a relatively small number of patients
in each subgroup, and age-stratified HRs especially should be inter-
preted with caution. The CCI has not been validated for use in chil-
dren, nor has it been validated for descriptive purposes, although it
has been used as such in a number of epidemiologic studies of Dan-
ish origin. The results from this study are only representative for
mastocytosis cases of a certain severity, and the incidence (espe-
cially in the child population) is most likely underestimated. The
study population was predominantly Caucasian, and our results
might not be generalizable to countries with a population compo-
sition that differs significantly from that of Scandinavian countries.
The effect of anaphylaxis and severe allergies were not integrated
as separate variables in our survival analyses but might explain the
higher mortality among some mastocytosis patients.
The increased mortality in our adult ISM category might be
interpreted as a consequence of a historical misclassification and
supports the integration of SSM as a future separate disease cate-
gory. We therefore suggest that standardized outpatient visits
could be limited to patients with CM whose disease history
includes suspicion of a systemic involvement (relapsing and unex-
plained cases of anaphylaxis, anaphylaxis due to wasp sting, and/or
pulsating abdominal pains) and patients who experience trouble-
some symptoms with the need for continued treatment and expert
guidance.
Conclusion
Based on historical Danish registry data, we discovered a
frequency of 65 new Danish cases of mastocytosis per year.
More children than adults were diagnosed with mastocytosis
(childhood-to-adult ratio was at least 1.6).
Over time, patients with ISM had a mortality rate that was
twice that of the background population. When adjusting for CCI,
the survival of patients with CM and ISMmoved toward one, which
suggests that CM and ISM may be benign diagnoses in isolation
and that the observed inferior survival may be a reflection of exist-
ing but unrecognized chronic diseases that are diagnosed when
patients enter a hospital setting. A possible explanation for the
persisting increased mortality observed in ISM, even after adjust-
ing for the categorical CCI, could be that this group includes
patients with SSM who are now known to have an increased
mortality. The decreased survival of infant mastocytosis cases is
difficult to interpret because the analysis was underpowered. Our
study highlights the need for precise diagnostic coding of these dis-
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